TherapeuticsMD Inc
Research TherapeuticsMD Inc (TXMD) on Bullrun: valuation model: 77.2% overvalued, market cap USD 25.93M, P/E 145.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTXMD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal77.2% overvalued
- Market capUSD 25.93M
- P/E145.5
- Financial periodFY2025
- RevenueUSD 3.02M
- Revenue growth71.6%
- Net income-USD 569.00K
Valuation Snapshot
Bullrun's latest valuation model marks TherapeuticsMD Inc as 77.2% overvalued; latest market cap is USD 25.93M; P/E is 145.5.
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system.
Frequently asked questions
Is TherapeuticsMD Inc overvalued or undervalued?
Bullrun's valuation model currently marks TherapeuticsMD Inc as 77.2% overvalued.
What is TherapeuticsMD Inc's market cap?
TherapeuticsMD Inc's market capitalization is USD 25.93M.
What is TherapeuticsMD Inc's P/E ratio?
TherapeuticsMD Inc's price-to-earnings (P/E) ratio is 145.5.
What does TherapeuticsMD Inc do?
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause;